CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenues:
Total revenues	$ 1,126,107	$ 1,054,969	$ 3,069,660	$ 2,980,777
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	128,880	111,611	349,768	317,000
Selling, general and administrative	530,647	325,772	1,403,059	1,016,007
Research and development	198,203	199,919	568,827	643,500
Intangible asset amortization	168,368	157,457	484,919	468,410
Acquired in-process research and development	42,500	0	947,862	10,000
Total operating expenses	1,068,598	794,759	3,754,435	2,454,917
Income (loss) from operations	57,509	260,210	(684,775)	525,860
Interest expense, net	(48,576)	(58,702)	(149,645)	(186,841)
Foreign exchange gain (loss)	102	(701)	(1,910)	(1,887)
Income (loss) before income tax benefit and equity in loss of investees	9,035	200,807	(836,330)	337,132
Income tax benefit	(242,424)	(14,533)	(277,406)	(33,517)
Equity in loss of investees	47	285	675	1,644
Net income (loss)	$ 251,412	$ 215,055	$ (559,599)	$ 369,005
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ 4.14	$ 3.50	$ (9.18)	$ 5.93
Diluted (in dollars per share)	$ 4.08	$ 3.42	$ (9.18)	$ 5.63
Weighted-average ordinary shares used in per share calculations - basic (in shares)	60,696	61,414	60,955	62,275
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	61,606	63,174	60,955	67,511
Product sales, net
Revenues:
Total revenues	$ 1,064,412	$ 989,707	$ 2,889,401	$ 2,795,953
Royalties and contract revenues
Revenues:
Total revenues	$ 61,695	$ 65,262	$ 180,259	$ 184,824